Practice teaching course on head and neck cancer management
|
|
- Lester Robbins
- 5 years ago
- Views:
Transcription
1 28-29 October Saint-Priest en Jarez, France Practice teaching course on head and neck cancer management IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION
2 Nicolas Magné France Locally advanced squamous cell carcinoma (LA/HNSCC) General principles of systemic therapies IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION
3 Locally advanced squamous cell carcinoma (LA/HNSCC) General principles of systemic therapies Nicolas Magné France
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19 Meta-analysis: Locoregional treatment with/without chemotherapy (93 trials; 17,346 patients) Trial Category Risk reduction (%) p-value Absolute benefit at 5 years (%) Adjuvant -6 NS -1 Neoadjuvant 4 NS 2.4 Concomitant Total Absolute benefit with concomitant platinum alone (cis or carbo): 11% Pignon JP, et al. Radiother Oncol 2009;92:4 14
20 RT + high-dose cisplatin (100mg/m 2 q3w x 3) was established by pivotal Phase III cooperative group trials Nasopharynx 1 RT + 100mg/m 2 cisplatin + adjuvant cisplatin (80mg/m 2 ) vs RT alone (Int 0099) Larynx 3 RT + 100mg/m 2 cisplatin vs induction followed by RT vs RT (RTOG 91-11) Unresectable disease 2 RT mg/m 2 cisplatin vs RT alone (Int 0126) Postoperative setting 4-5 RT + 100mg/m 2 cisplatin vs RT alone (RTOG 9501) RT + 100mg/m 2 cisplatin vs RT alone (EORTC 22931) 1. Al-Sarraf M, et al. J Clin Oncol 1998;16: ; 2. Adelstein DJ, et al. J Clin Oncol 2003;21:92 98; 3. Forastiere AA, et al. N Engl J Med 2003;349: ; 4. Cooper JS, et al. N Engl J Med 2004;350: ; 5. Bernier J, et al. N Engl J Med 2004;350:
21 High-dose cisplatin is recognized as the gold standard treatment in LA SCCHN 1 but few studies have investigated this regimen Published study Cisplatin monotherapy (100mg/m 2 q3w) + RT Study Total patients in study Excludes adjuvant (post-surgery) CRT RT alone comparator arm Of the 17,346 patients included in the meta-analysis, 651 non-resected patients were treated with cisplatin + RT, and only: Studies including standard-dose (100mg/m 2 q3w) cisplatin monotherapy + RT: 2 Post-surgery? Published? patients with non-resected LA SCCHN were randomized to cisplatin 100mg/m 2 q3w EORTC Yes Yes 142 EORTC No No as recommended in the guidelines EORTC No No HeCOG No Yes Int No Yes RTOG No Yes RTOG Yes Yes 1. NCCN Guidelines: Head and Neck Cancers V1.2015; 2. Pignon JP, et al. Radiother Oncol 2009;92:4 14
22 Cisplatin + RT is associated with substantial acute and late toxicity Grade 3 toxicities with 100mg/m 2 q3w cisplatin + RT vs RT alone in LA SCCHN 1 RTOG analysis of three prospective studies of cisplatin + RT in LA SCCHN (N=230) 2 Toxicity, % Highdose cisplati n CRT (n=95) RT alone (n=98) Overall Mucositis/ dysphagia Nausea/vomit ing p-value < Leukopenia 40 1 <0.001 Thrombocyto penia 3 0 NS Anemia 17 0 <0.001 Concerns around acute/late toxicity may preclude patients from receiving the recommended dose of cisplatin 3 5 Renal Skin 7 13 NS *Late toxicity was defined as chronic Grade 3 4 pharyngeal/laryngeal toxicity; requirement 22 This for is a where feeding all tube footnotes 2 years and references after registration; go. and/or potential treatment-related death (e.g. pneumonia) within 3 years Any late toxicity* Pharyngeal dysfunction Laryngeal dysfunction Feeding tube dependence Other Death 2% 12% 13% 10% 27% 43% Patients (%) 1. Adelstein DJ, et al. J Clin Oncol 2003;21:92 98; 2. Machtay M, et al. J Clin Oncol 2008;26: ; 3. Espeli V, et al. Oral Oncology 2012;48: ; 4. Bernier J, et al. N Engl J Med 2004;350: ; 5. Argiris A, et al. Clin Cancer Res 2004;10:
23 Percentage of patients Compliance with high-dose cisplatin is poor because of significant toxicities Completed cisplatin cycles Cisplatin cycles started on time 3-weekly 100mg/m 2 cisplatin concurrent with IMRT* 1 1 cycle 3-weekly 100mg/m 2 cisplatin concurrent with RT 2 No CT 1 cycle Post-operative 3-weekly 100mg/m 2 cisplatin concurrent with conventionally fractionated RT cycles 2 cycles cycles 3 cycles 20 0 Cycle 1 Cycle 2 Cycle 3 54% of patients completed the full 3 cycles of high-dose cisplatin 61% of patients completed the full 3 cycles of high-dose cisplatin 49% of patients started their third cycle on time *Retrospective data 1. Espeli V, et al. Oral Oncology 2012;48: ; 2. Cooper JS, et al. N Engl J Med 2004;350: ; 3. Bernier J, et al. N Engl J Med 2004;350:
24 Multiple factors may render a patient unsuitable for high-dose (100mg/m 2 ) cisplatin Cisplatin is contraindicated in patients with: >2 Poor performance status 1 Renal dysfunction (CrCl <50mL/min) 1,2 Neurologic disorders (>grade 1 neuropathy) 1 Otologic disorders (pre-existing hearing loss or tinnitus >grade 2) 1,2 Known hypersensitivity to platinum-based therapy 1,2 CrCl, creatinine clearance 1. Ahn MJ. Oral Oncol 2016;53:10 16; 2. Cisplatin SmPC, January 2016
25 Patients with certain characteristics are at high risk of cisplatinassociated complications 1 Patient factors, e.g. Age >70 1,2 Involuntary weight loss 20% 2 ECOG >1 2 Socioeconomic status/ social support 2 Comorbidities: Renal dysfunction (CrCl 50 60mL/min) 2,3 Cardiovascular disease 2 Treatment factors, e.g. Prior cisplatin treatment (e.g. TPF) 2 Borderline ear function (grade 1) 2 CrCl, creatinine clearance 1. Machtay M, et al. J Clin Oncol 2008;26: ; 2. Ahn MJ. Oral Oncol 2016;53:10 16; 3. Miller RP, et al. Toxins 2010;2:
26 Probability of survival Probability of survival Weekly cisplatin: Concerns for reduced efficacy in LA SCCHN CRT with 3-weekly (100mg/m 2 ) vs weekly (40mg/m 2 ) cisplatin in patients with LA SCCHN (retrospective analysis) 1 CRT with weekly (20mg/m 2 ) cisplatin vs RT alone in patients with LA SCCHN (Phase III ECOG) HR=0.50 (95% CI: ) p= No significant difference in OS p= Cisplatin 100mg/m 2 q3w (n=54) Cisplatin 40mg/m 2 qw (n=40) 0.8 Cisplatin 20mg/m 2 qw + RT (n=149) RT alone (n=159) Median OS, 4.3 years Median OS, 1.9 years Time (years) Time (years) Ongoing Japanese non-inferiority study (JCOG 1008) is comparing RT plus cisplatin 40mg/m 2 qw with RT plus high-dose cisplatin 100mg/m 2 q3w as postoperative CRT in patients with high-risk LA SCCHN 3 1. Espeli V, et al. Oral Oncol 2012;48: ; 2. Quon H, et al. Int J Radiat Oncol Biol Phys 2011;81: ; 3. Kunieda F, et al. Jpn J Clin Oncol 2014;44:
27 Toxicity with weekly vs 3-weekly cisplatin Randomized trial: Postoperative CRT with 3-weekly cisplatin (100mg/m 2 )* vs weekly cisplatin (40mg/m 2 ) in patients with oral cavity SCCHN Neutropenia Leukopenia Anemia Nausea/vomitin g Dermatitis Laryngeal edema Stomatitis Pharyngitis Mucositis Patients, % Acute toxicity Cisplatin 100mg/m 2 q3w (n=26) Cisplatin 40mg/m 2 qw (n=24) p=0.012 Cisplatin 100mg/m 2 q3w (n=26) Cisplatin 40mg/m 2 qw (n=24) Grade Grade Grade Cisplatin 200mg/m p- value Patients with grade 3 acute toxicities, % Although OS and locoregional recurrence-free survival did not differ significantly between arms, the study was underpowered for the comparison of efficacy outcomes *Hydration with saline solution (500ml 2 hours before and after cisplatin infusion) was mandatory in the high-dose cisplatin arm only Tsan DL, et al. Radiat Oncol 2012;7:215
28 Proportion of patients, % Cetuximab has demonstrated significant efficacy in a well-designed, landmark Phase III study 1 4 Phase III Bonner study: 100 Overall survival 5 year follow up 1,2 Cetuximab + RT (n=211) RT alone (n=213) RT alone n=21 3 Cetuxima b + RT n=211 Median LRC* (months) 1 HR (95% CI) 0.68 ( ) p- value months HR=0.73 (95% CI: ) p= months 5-year OS 46% Median OS (months) ( ) % Median PFS (months) ( ) Time (months) *Primary endpoint; LRC, locoregional control 1. Bonner JA, et al. N Engl J Med 2006;354: ; 2. Bonner JA, et al. Lancet Oncol 2010;11:21 28; 3. Wirth LJ. J Clin Oncol 2016;34: ; 4. Griffin S, et al. Health Technol Assess 2009;13 Suppl 1:49 54
29 Baseline EORTC QLQ-C30 global health status (leastsquares mean) Cetuximab does not exacerbate the toxicity seen with RT* and does not impact on QoL Bonner study 1,2 Grades 3 5 adverse events 1 Quality of life 2 Mucositis Dysphagia RT (n=212) Cetuximab + RT (n=207) Radiation dermatitis Xerostomia p=0.103 Acne-like rash Infusion reactions* p=0.01 p<0.001 RT alone (n=212) Cetuximab + RT (n=208) Week 4 Month 4 Month 8 Month 12 Patients (%) The median 29 duration of mucositis and dysphagia in the overall population was similar in both treatment groups (p=0.17) 2 *Except for acne-like rash and infusion reactions 1. Bonner JA, et al. N Engl J Med 2006;354: ; 2. Curran D, et al. J Clin Oncol 2007;25:
30 1. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers V1.2015; 2. Pignon JP, et al. Radiother Oncol 2009;92:4 14; 3. Adelstein DJ, et al. J Clin Oncol 2003;21:92 98; 4. Machtay M, et al. J Clin Oncol 2008;26: ; 5. Espeli V, et al. Oral Oncology 2012;48: ; 6. Bonner JA, et al. N Engl J Med 2006;354: ; 7. Calais G, et al. J Natl Cancer Inst 1999;91: ; 8. Wirth LJ. J Clin Oncol 2016;34: ; 9. Griffin S, et al. Health Technol Assess 2009;13 Suppl 1:49 54; 10. Bonner JA, et al. Lancet Oncol 2010;11:21 28; 11. Curran D, et al. J Clin Oncol 2007;25: ; Cetuximab + RT is an evidence-based option with a good therapeutic index in patients not suitable for high-dose cisplatin + RT 1 Category 1 Regimen (+ RT) Cisplatin 100mg/m 2 Carboplatin + 5-FU Cetuximab Considerations Survival benefit vs RT alone 2 Can lead to severe acute and late toxicities 3,4 Associated with poor compliance 5,6 Improves OS vs RT alone 7 Associated with substantial acute toxicities 7 Efficacy and safety established in a well-designed, landmark Phase III trial 6,8,9 Does not exacerbate toxicity of RT 6,10,11
31 Progression-free-survival Overall survival GORTEC : RT/cetuximab vs RT/cetuximab/carboplatin/5-FU PFS: HR* 0.73 ( ) 2-sided log-rank p=0.015 OS: HR* 0.80 ( ) 2-sided log-rank p= CT /cetuximab/rt Cetuximab/RT CT /cetuximab/rt Cetuximab/RT 0.00 No. at risk: CT /cetux/rt 204 Cetux/RT Years since randomization No. at risk: CT /cetux/rt Cetux/RT Years since randomization PFS at 3 years (95% CI): CT /cetuximab/rt 52.3% (45 59) Cetuximab/RT 40.5% (34 48) OS at 3 years (95% CI): CT /cetuximab/rt 60.8% (54 67) Cetuximab/RT 54.9% (48 62) Toxicity was increased in the intensified regimen *HR adjusted for N (0 vs 1 2), T (0 2 vs 3 4) and center in Cox model CT consisted of carboplatin + 5-FU 1. Bourhis J, et al. ASCO 2016 (Abstract No. 6003)
32 Cetuximab + RT is a category 1 evidence-based option for all patients with LA SCCHN 1 * NCCN category 1 evidence-based options for treatment of LA SCCHN 1 Cisplatin 100mg/m 2 q3w + RT? Cetuximab + RT? 2,3 Carboplatin/5-FU + RT* 32 *Outcome of the advisory board Determining unsuitability for cisplatin + RT 11/02/2016 Unsuitable High-risk patients Suitable Suitability for cisplatin 100mg/m 2 q3w + RT 1. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers V1.2015; 2. Hitt R, et al. ASCO 2016 (Abstract No. 6001); 3. Geoffrois L, et al. ASCO 2016 (Abstract No. 6000)
33 New elements in the continuum of care in recurrent and/or metastatic SCCHN? 1st line 2nd and later lines Cetuximab + platinumbased CT cetuximab until PD? Taxane +/- platin Cetuximab* +/- taxane Cetuximab* Methotrexate Checkpoint inhibitors *Cetuximab monotherapy or in combination with taxane is not approved for the treatment of SCCHN in the EU 2 Checkpoint inhibitors are not currently approved for the treatment of SCCHN CT, chemotherapy; PD, progressive disease 1. NCCN Clinical Practice Guidelines in Oncology. Head and Neck Cancers. V ; 2. Erbitux SmPC, June 2014.
34 EXTREME regimen improves response and symptom control in 1st line 1,2 Response rates in EXTREME: 1,3 Real-life importance of tumor shrinkage with cetuximab % 6.8% Cetuximab + CT* CR PR 20% 0.9% CT* alone *CT consisted of cisplatin/carboplatin + 5- FU 1. Vermorken JB, et al. N Engl J Med 2008;359: ; 2. Mesia et al. EMA assessment report, Erbitux, Available at _Variation/human/000558/WC pdf (Accessed 19 February 2016); 3. Mesía R, et al. Ann Oncol 2010;21:
35 OS (%) Cetuximab + platinum-based CT followed by cetuximab maintenance: efficacy outcomes Cetuximab + CT* (n=222) 100 CT* alone (n=220) HR=0.80, p= months 10.1 months 81% disease control in the cetuximab arm Months *CT consisted of cisplatin/carboplatin + 5-FU Vermorken JB, et al. N Engl J Med 2008;359:
36 OS (probability) High response rates and promising mos with TPEx TPEx Phase II study 1 : Cis/doceT+cet OS TPEx real-world study 2 : OS Median OS: 14.0 months (95% CI: ) % 57.4% Median OS: 13.6 months (95% CI: NR) % 19.0% Time (months) Time (months) No. at risk ORR: 44% 80% disease stabilization ORR: 86% 97% disease stabilization *taxanes are not approved for R/M SCCHNin the EU 3 Cetuximab administered every 2 weeks at 500mg/m 2 in the maintenance phase (Note: off-label use 3 ) 1. Guigay J, et al. Ann Oncol 2015;26: ; 2. Even C, et al. ESMO 2014 (Abstract No. 997P); 3. Erbitux SmPC, June 2014.
37 OS (percentage) CSPOR-HN02 study: Carbo/pacliT+ cet OS Median OS: 14.7 months (95% CI: 12.1 NR) 60 ORR: 40% 60% disease stabilization Time from registration (months) No. at risk Chemotherapy for R/M SCCHN. Chemotherapy consisted of paclitaxel 100mg/m 2 on day 1, 8; carboplatin AUC 2.5 on day 1, 8, repeated every 3 weeks for up to 6 cycles; and cetuximab at an initial dose of 400mg/m 2, followed by 250mg/m 2 weekly until disease progression or unacceptable 37 Tahara M, et al. ASCO 2016 (Abstract No. 6026);
38 The ability of cetuximab to induce ADCC may contribute to its clinical efficacy 1,2 1. Trivedi S, et al. Ann Oncol 2015;26:40 47; 2. Belluci R, et al. OncoImmunol 2015;4:6,e ; 3. Lo Nigro C, et al. Cancer Res 2015;75:1327. NK cell activation 1 EGFR Lysis 1 Tumor cell Cetuximab NK cell FC Receptor Dendritic cell activation and T cell recruitment 2 Tumor cell FC region of antibody
39 and could contribute to synergy with checkpoint inhibition NK cell activation 1 IFNγ 2 EGFR Tumor cell Cetuximab PD-L1 2 Cetuximab also attenuates the decrease in T and NKT cells seen with platinum + 5-FU 3 1. Trivedi S, et al. Ann Oncol 2015;26:40 47; 2. Belluci R, et al. OncoImmunol 2015;4:6,e ; 3. Lo Nigro C, et al. Cancer Res 2015;75:1327.
40 New elements in the continuum of care in recurrent and/or metastatic SCCHN? 1st line 2nd and later lines Cetuximab + platinumbased CT cetuximab until PD? Taxane +/- platin Cetuximab* +/- taxane Cetuximab* Methotrexate Checkpoint inhibitors *Cetuximab monotherapy or in combination with taxane is not approved for the treatment of SCCHN in the EU 2 Checkpoint inhibitors are not currently approved for the treatment of SCCHN CT, chemotherapy; PD, progressive disease 1. NCCN Clinical Practice Guidelines in Oncology. Head and Neck Cancers. V ; 2. Erbitux SmPC, June 2014.
41 CheckMate 141, KEYNOTE-55 & KEYNOTE-012 Study designs CheckMate KEYNOTE-055 2,3 N=361 N=172 KEYNOTE N=192 *ITT population (Note: 13 patients actually received cetuximab); ASCO 2016 data cover analysis of the first 50 patients 1. Ferris RL, et al. ASCO 2016 (Abstract No. 6009); 2. Bauml J, et al. ASCO 2016 (Abstract No. 6011); 3. (Accessed May 29, 2016); 4. Chow LQ, et al. ASCO 2016 (Abstract No. 6010)
42 CheckMate 141 and KEYNOTE-055: Inclusion criteria CheckMate KEYNOTE-055 2,3 Age 18 years PS 1 R/M SCCHN not amenable to curative local therapy Tumor progression or recurrence within 6 months of last dose of platinum therapy in the adjuvant, recurrent or metastatic setting Measurable disease by CT or MRI Age 18 years PS 1 R/M SCCHN not amenable to curative local therapy Tumor progression or recurrence within 6 months of any number of platinum-bases and cetuximab therapy lines in the adjuvant, recurrent or metastatic setting Must be resistant (not responding) to both platinum and cetuximab Measurable disease by CT or MRI 1. Ferris RL, et al. ASCO 2016 (Abstract No. 6009); 2. Bauml J, et al. ASCO 2016 (Abstract No. 6011); 3. (Accessed May 29, 2016).
43 New potential options in 2nd line R/M SCCHN Nivolumab 1 Pembrolizumab 2 Nivolumab CheckMate vs IC n=240 ORR, % 13.3 vs 5.8 (NS) CR, % 2.5 vs 0.8 PR, % 10.8 vs 5.0 SD, % 22.9 vs 35.5 PD, % 41.7 vs 34.7 Not determined mpfs (mo) 22.1 vs vs 2.3 (NS) KEYNOTE n=92 ORR, % 17 PR, % 17 SD, % 19 PD, % 55 Not applicable 9 Patients with 6 months followup ORR, overall response rate; CR complete response; PD, progressive disease; PR, partial response; SD, stable disease. 1. Ferris RL, et al. ASCO 2016 (Abstract No. 6009); 2. Bauml J, et al. ASCO 2016 (Abstract No. 6011).
44 Overall survival (ITT population) CheckMate 141 KEYNOTE Ferris RL, et al. ASCO 2016 (Abstract No. 6009); 2. Bauml J, et al. ASCO 2016 (Abstract No. 6011).
45 Progression-free survival (ITT population) CheckMate 141 KEYNOTE This is where all footnotes and references go. 1. Ferris RL, et al. ASCO 2016 (Abstract No. 6009); 2. Bauml J, et al. ASCO 2016 (Abstract No. 6011).
46 Relevance of biomarkers: PD-L1 expression 1. Ferris RL, et al. ASCO 2016 (Abstract No. 6009)
47 Relevance of biomarkers: PD-L1 expression 1. Ferris RL, et al. ASCO 2016 (Abstract No. 6009)
48 Relevance of biomarkers: PD-L1 expression 1. Ferris RL, et al. ASCO 2016 (Abstract No. 6009)
49 ORR and OS by PD-L1 expression CheckMate (nivolumab arm only) n=240 1 % KEYNOTE ,3 n=92 KEYNOTE * PD-L1 PD-L1 PD-L1 5% 10% + + ORR, % Median OS, months Median PFS, months NR NR *Data for tumor and inflammatory cells Estimated from data provided in days (303 and 151, respectively) 49 This is where all footnotes and references go. 1. Ferris RL, et al. ASCO 2016 (Abstract No. 6009); 2. Bauml J, et al. ASCO 2016 (Abstract No. 6011); 3. (Accessed May 29, 2016); 4. Chow LQ, et al. ASCO 2016 (Abstract No. 6010)
50 Other biomarkers (KEYNOTE-012) ORR by PD-L2 status Nonresponders n Responder s n ORR, % (95% CI) p- value 50 CPS (tumor and inflammatory cells) This is where all footnotes and references go. PD- L2+ PD- L (15 31) (4 20) Chow LQ, et al. ASCO 2016 (Abstract No. 6010)
51 Best of both worlds in future treatment concepts? ADCC and T cell receptor regulation NK cell Tumor cell FC Receptor FC region of antibody Regulation of T-cell activation This is where all footnotes and references go. 1. Janeway CA Jr, et al. Immunobiology; The immune system in health and disease; 5 th Ed. 2001; 2. Pardoil DM. Nat Rev Cancer 2012; 12:
52 First line R/M ongoing development strategies: Answering all the questions? Questions being answered in the ongoing Phase 3 studies Study KESTREL 1 (N=628) Phase III KEYNOTE (N=780) Phase III CHECKMAT E (N=490) Phase III NCT (N=104) Phase I Others? Comparator arm(s) MEDI4736 MEDI tremelimumab Cetuximab + platinum + 5-FU Pembrolizumab Pembrolizumab + platinum + 5-FU Cetuximab + platinum + 5-FU Mono checkpoi nt? Chemo +ionc? ionc combi? EXTREM E combi? Maintena nce ionc switch? Nivolumab + ipilimumab Cetuximab + platinum + 5-FU Urelumab + cetuximab
Current patient journey in SCCHN
Contents Current patient journey in SCCHN 1 st line options for R/M SCCHN 2 nd line treatmens options for R/M SCCHC The evolving continuum of care in R/M SCCHH Current patient journey in SCCHN 1. Mabanta
More informationLaryngeal and hypopharyngeal cancers
Laryngeal and hypopharyngeal cancers Induction Chemotherapy in combined modality approaches Atenas 16.09.2017 Ana Ferreira Castro, MD Medical Oncology Centro Hospitalar do Porto Instituto de Ciências Biomédicas
More informationEmerging Role of Immunotherapy in Head and Neck Cancer
Emerging Role of Immunotherapy in Head and Neck Cancer Jared Weiss, MD Associate Professor of Medicine and Section Chief of Thoracic and Head/Neck Oncology UNC Lineberger Comprehensive Cancer Center Copyright
More informationUpdate on the development of immune checkpoint inhibitors
Update on the development of immune checkpoint inhibitors Jean-Pascal Machiels Department of Medical Oncology Laboratory of Medical Oncology Cliniques universitaires Saint-Luc Université catholique de
More informationState of the Art: Management of Squamous Cell Carcinoma of the Head and Neck. Raul Giglio
State of the Art: Management of Squamous Cell Carcinoma of the Head and Neck Raul Giglio Disclosures Nothing to disclose SCCHN Outline 1. General considerations: MTD 2. Epidemiology 3. Locoregional disease
More informationNeoplasie della testa e del collo e trattamenti combinati
Neoplasie della testa e del collo e trattamenti combinati 2 nd Young Sicilian Oncologists Day: Linee Guida AIOM, Appropriatezza e Medicina di precisione Messina 12-13 Ottobre 2017 NERINA DENARO denaro.n@ospedale.cuneo.it
More informationConcurrent Chemo- and Radiotherapy for Ororpharynx Cancer
Concurrent Chemo- and Radiotherapy for Ororpharynx Cancer Faye Johnson MD, PhD Associate Professor Thoracic/Head and Neck Medical Oncology August 2017 Objectives Review data that support concurrent chemo-
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationSequencing Chemo with Radiation therapy Locally Advanced Head and Neck Cancer. Dr P Vijay Anand Reddy Director Apollo Cancer Hospital
Sequencing Chemo with Radiation therapy Locally Advanced Head and Neck Cancer Dr P Vijay Anand Reddy Director Apollo Cancer Hospital H&N Ca - Disease Burden 15-20% of all cancers in India, 8% worldwide
More informationNeoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck. Mei Tang, MD
Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck Mei Tang, MD Head and Neck Cancer Worldwide New cases : 644,000 Cancer deaths: 350,000 About 5% of all cancers Local Recurrence:
More informationCetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice?
Cent. Eur. J. Med. 9(2) 2014 279-284 DOI: 10.2478/s11536-013-0154-9 Central European Journal of Medicine Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice? Jacopo Giuliani* 1, Marina
More informationThe PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer
The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer Robert I. Haddad, Guilherme Rabinowits, Roy B. Tishler,
More informationState of the art for radiotherapy of SCCHN
State of the art for radiotherapy of SCCHN Less side effects Cured More organ & function preservation Head & neck cancer = 42 000 new cases / year in Europe Not cured Local failure Distant failure More
More informationSAMO MASTERCLASS HEAD & NECK CANCER. Nicolas Mach, PD Geneva University Hospital
SAMO MASTERCLASS HEAD & NECK CANCER Nicolas Mach, PD Geneva University Hospital Epidemiology Prevention Best treatment for localized disease Best treatment for relapsed or metastatic disease Introduction
More informationRT +/- Surgery. Concurrent ChemoRT +/- Surgery
Molecular targeted approaches to head and neck cancer Lillian L. Siu Department of Medical Oncology & Hematology Princess Margaret Hospital, University of Toronto Locally Advanced HNSCC Locally Advanced
More informationHead and NeckCancer: multi-modal therapeuticintegration
Head and NeckCancer: multi-modal therapeuticintegration P. Ponticelli, L. Lastrucci, R. De Majo, A. Rampini U.O.C. Radioterapia Ospedale S. Donato ASL 8 -AREZZO Summary Biological considerations Clinical
More informationDisclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor
Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical
More informationINMUNOTERAPIA: NUEVO PARADIGMA EN LOS TUMORES DE CABEZA Y CUELLO. Dra. Lara Iglesias H.U.12 Octubre
INMUNOTERAPIA: NUEVO PARADIGMA EN LOS TUMORES DE CABEZA Y CUELLO Dra. Lara Iglesias H.U.12 Octubre INTRODUCCIÓN INFORME SEOM DE EVALUACIÓN DE FÁRMACOS: NIVOLUMAB EN CÁNCER EPIDERMOIDE DE CABEZA Y CUELLO
More informationNeoplasie del laringe Diagnosi e trattamento
Neoplasie del laringe Diagnosi e trattamento Venerdì 22 maggio 2015 Alessandria Trattamenti non chirurgici: Preservazione d organo, malattia localmente avanzata Marco C Merlano A.O. S.Croce e Carle, Ospedale
More informationPresent and Future of Head and Neck Cancer Therapy (Focus at systemic therapy)
Present and Future of Head and Neck Cancer Therapy (Focus at systemic therapy) Jan B; Vermorken, MD, PhD Department of Medical Oncology Antwerp University Hospital Edegem, Belgium 1st Hellenic Conference
More information1 st Appraisal Committee meeting Background & Clinical Effectiveness Gillian Ells & Malcolm Oswald 24/11/2016
Lead team presentation Nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy [ID971] 1 st Appraisal Committee meeting Background
More informationRecent Advances & Ongoing Challenges in Head & Neck Cancers
Recent Advances & Ongoing Challenges in Head & Neck Cancers Robert Haddad, MD Disease Center Leader Head and Neck Oncology Program Dana Farber Cancer Institute Harvard Medical School Boston, MA Disclosures
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationOrgan-Preservation Strategies in head and neck cancer. Teresa Bonfill Abella Oncologia Mèdica Parc Taulí Sabadell. Hospital Universitari
Organ-Preservation Strategies in head and neck cancer Teresa Bonfill Abella Oncologia Mèdica Parc Taulí Sabadell. Hospital Universitari Larynx Hypopharynx The goal of treatment is to achieve larynx preservation
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationAdjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationOptions for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationHead and Neck cancer
Head and Neck cancer Medical Oncologist s Role in Multidisciplinary Teams - Focus on Adjuvant & Neo-adjuvant Therapy - Hye Ryun Kim, M.D. Yonsei Cancer Center, Medical Oncology Contents I. Introduction
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationLocally advanced head and neck cancer
Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationNon-surgical treatment for locally advanced head and neck squamous cell carcinoma: beyond the upper limit
Editorial Non-surgical treatment for locally advanced head and neck squamous cell carcinoma: beyond the upper limit Hiroto Ishiki, Satoru Iwase Department of Palliative Medicine, The Institute of Medical
More informationCURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER
CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER Jean-Pascal Machiels Department of medical oncology Institut I Roi Albert II Cliniques universitaires Saint-Luc Université catholique de Louvain, Brussels,
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationCarla van Herpen Medical Oncologist Immunotherapyin Head & NeckCancer
Carla van Herpen Medical Oncologist 01-10-2016 Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial,
More informationTreatment of Locally Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck
Review Article imedpub Journals http://www.imedpub.com/ Head and Neck Cancer Research ISSN 2572-2107 Treatment of Locally Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck Chukwuemeka V
More informationA Giant Leap in the Treatment Options for Advanced Bladder Cancer
A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France Clinical Features of Bladder Cancer
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationIs the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Prague July 2016 State of the art: Standard of care for anal squamous cancer Rob Glynne-Jones Mount Vernon Cancer Centre Aim to discuss Background The trials
More informationNew Paradigms for Treatment of. Erminia Massarelli, MD, PHD, MS Clinical Associate Professor
New Paradigms for Treatment of Head and Neck cancers Erminia Massarelli, MD, PHD, MS Clinical Associate Professor City of Hope Disclosure Statement Grant/Research Support frommerck Bristol Grant/Research
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationMultimodular treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)
Multimodular treatment in Head and Neck Squamous Cell Carcinoma (HNSCC) Amanda Psyrri, MD,FACP Attikon University Hospital Athens, Greece Learning objectives After reading and reviewing this material,
More information17th ESO-ESMO Masterclass Clinical Oncology
Chemoradiotherapy and Systemic Therapy in Squamous Cell Carcinoma of the Head and Neck (SCCHN) Jan B. Vermorken, MD, PhD Department of Medical Oncology Antwerp University Hospital Edegem, Belgium 17 th
More informationImmunotherapy in head and neck cancer and MSI in solid tumors
Immunotherapy in head and neck cancer and MSI in solid tumors Brian Hunis, MD, MBA Associate Medical Director, Memorial Cancer Institute. Hollywood, FL »No disclosures Objectives»Discuss the role of immunology
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationLarynx Hypopharynx. Therapy algorithms. Why larynx preservation at all? State of the art Jean Louis Lefebvre,Lille Jan Klozar,Prague
Larynx Hypopharynx Moderation Rainald Knecht,Hamburg State of the art Jean Louis Lefebvre,Lille Debate pro CRT Jan Klozar,Prague contra CRT Marshall Posner,Boston Clinical cases all Therapy algorithms
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationThe International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology
The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology www.ifhnos.net The International Federation of Head and Neck Oncologic Societies
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationHead and Neck Cancer:
Head and Neck Cancer: Robert Haddad M.D. Clinical Director Head and Neck Oncology Program Dana Farber Cancer Institute Boston, MA Predictive Biomarkers: HPV Abstract 6003: Survival Outcomes By HPV Status
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationHEAD AND NECK CANCER TREATMENT REGIMENS (Part 1 of 5)
HEAD AND NECK CANCER TREATMENT S (Part 1 of 5) Clinical Trials: The National Comprehensive Cancer Network (NCCN) recommends cancer patient participation in clinical trials as the gold standard for treatment.
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationand neck cancers, 2018
Emerging systemic treatments for head and neck cancers, 2018 A. DIMITRIOS COLEVAS, MD PROFESSOR OF MEDICINE (ONCOLOGY) AND, BY COURTESY, OF OTOLARYNGOLOGY - HEAD AND NECK SURGERY AT THE STANFORD UNIVERSITY
More informationScottish Medicines Consortium
Scottish Medicines Consortium cetuximab 2mg/ml intravenous infusion (Erbitux ) (279/06) MerckKGaA No 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationLaryngeal Preservation Using Radiation Therapy. Chemotherapy and Organ Preservation
1 Laryngeal Preservation Using Radiation Therapy 1903: Schepegrell was the first to perform radiation therapy for the treatment of laryngeal cancer Conventional external beam radiation produced disappointing
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationThe Role of Concurrent Chemo-radiotherapy in Patients with Head and Neck Cancers: A Review
The Role of Concurrent Chemo-radiotherapy in Patients with Head and Neck Cancers: A Review M.D. Al-Sarraf 1 1 Williams Beaumont Hospital, Royal Oak, Michigan, USA Introduction In the past, radiotherapy
More informationHPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV
More informationAre we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
More informationRADIATION THERAPY AND CHEMOTHERAPY IN LOCALLY ADVANCED CANCER OF THE HEAD AND NECK Carlos A. Perez, M.D. Former Chairman/Professor Emeritus
RADIATION THERAPY AND CHEMOTHERAPY IN LOCALLY ADVANCED CANCER OF THE HEAD AND NECK Carlos A. Perez, M.D. Former Chairman/Professor Emeritus Department of Radiation Oncology Mallinckrodt Institute of Radiology/
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More information5/20/ ) Haffty GB: Concurrent chemoradiation in the treatment of head and neck cancer. Hematol. Oncol. Clin: North Am.
Prague, 24-25 25 April 29 ALTERNATING CHEMORADIATION: FOR WHOM? M. Merlano MD Holy Cross Gen. Hospital Cuneo - Italy ALTERNATING CHEMORADIATION: FOR WHOM? Definition of alternating chemoradiation Targets
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationRole of immunotherapy in virus related head and neck cancer Nerina Denaro
Role of immunotherapy in virus related head and neck cancer Nerina Denaro Oncologia ASO S. Croce e Carle Cuneo Virus-related HNC HNSCC (oropharynx) HPV Nasopharyngeal Cancer (NPC) EBV EBV 1 st human virus
More informationLocoregionally advanced squamous cell carcinoma of the head and neck: chemoradiation or bioradiation
Editorial Locoregionally advanced squamous cell carcinoma of the head and neck: chemoradiation or bioradiation Pol Specenier 1,2, Jan B. Vermorken 1,2 1 Department of Medical Oncology, Antwerp University
More informationHead and Neck Reirradiation: Perils and Practice
Head and Neck Reirradiation: Perils and Practice David J. Sher, MD, MPH Department of Radiation Oncology Dana-Farber Cancer Institute/ Brigham and Women s Hospital Conflicts of Interest No conflicts of
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationUrothelial Cancers- New Strategies. Sandy Srinivas.MD Stanford University
Urothelial Cancers- New Strategies Sandy Srinivas.MD Stanford University Relevant financial relationships in the past twelve months by presenter or spouse/partner. Consultant: Genentech, Astra Zeneca The
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationHEAD AND NECK CANCER TREATMENT REGIMENS (Part 1 of 5)
HEAD AND NECK CANCER TREATMENT S (Part 1 of 5) Clinical Trials: The National Comprehensive Cancer Network (NCCN) recommends cancer patient participation in clinical trials as the gold standard for treatment.
More informationTOXICITY OF TWO CISPLATIN-BASED RADIOCHEMOTHERAPY REGIMENS FOR THE TREATMENT OF PATIENTS WITH STAGE III/IV HEAD AND NECK CANCER
ORIGINAL ARTICLE TOXICITY OF TWO CISPLATIN-BASED RADIOCHEMOTHERAPY REGIMENS FOR THE TREATMENT OF PATIENTS WITH STAGE III/IV HEAD AND NECK CANCER Dirk Rades, MD, 1 Fabian Fehlauer, MD, 2 Mashid Sheikh-Sarraf,
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationGuillaume Janoray, Yoann Pointreau, Pascal Garaud, Sophie Chapet, Marc Alfonsi, Christian Sire, Eric Jadaud, Gilles Calais
JNCI J Natl Cancer Inst (016) 108(4): djv368 doi:10.1093/jnci/djv368 First published online December 16, 015 Article Long-Term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy
More informationHead&Neck, and Thyroid Cancers: Incorporating New Therapies into Current Treatment Algorithms
Head&Neck, and Thyroid Cancers: Incorporating New Therapies into Current Treatment Algorithms Robert Haddad, MD Disease Center Leader Head and Neck Oncology Program Dana Farber Cancer Institute Harvard
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationHead and Neck Cancer Update Sandro V Porceddu
Head and Neck Cancer Update Sandro V Porceddu Director, Radiation Oncology Research Princess Alexandra Hospital, Brisbane Associate Professor, University of Queensland President, Trans Tasman Radiation
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationRecurrent or Metastatic H&N Cancer Advances and New Strategies
Recurrent or Metastatic H&N Cancer Advances and New Strategies Jan B. Vermorken, MD, PhD Department of Medical Oncology Antwerp University Hospital Edegem, Belgium II International Symposium on Head and
More informationNasopharyngeal Cancer/Multimodality Treatment
Nasopharyngeal Cancer/Multimodality Treatment PANAGIOTIS KATSAOUNIS Medical Oncologist IASO GENERAL HOSPITAL Athens, 22/10/2016 1 st Hellenic Multidisciplinary Conference on Head and Neck Cancer INTRODUCTION
More information非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More information